Clinical Trial

A Phase I Clinical Study of SSS59 Monotherapy in Patients With Advanced Malignant Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study was an open-label phase I study to evaluate the safety, pharmacokinetics, and antitumor activity of SSS59 as a single agent in patients with advanced malignancies.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-23.
Status change: Not Yet Recruiting → Recruiting 2025-04-27
Trial Details
NCT Number NCT06944444
Lead Sponsor Shenyang Sunshine Pharmaceutical Co., LTD.
Conditions Malignant Tumors
Enrollment 154 participants
Start Date 2025-04-27
Primary Completion 2027-03-01 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-04-29